Core Viewpoint - Tiger Med's stock rose by 2.18% on March 31, with a trading volume of 1.167 billion yuan and a market capitalization of 46.349 billion yuan [1][10]. Group 1: Company Overview - Hangzhou Tiger Med Technology Co., Ltd. specializes in providing comprehensive clinical trial services for new drug development as a Contract Research Organization (CRO) [2][11]. - The company offers a range of services including clinical operations, clinical pharmacology, regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party audits, data management, and statistical analysis [2][11]. - Tiger Med has established itself as a leading CRO in China, focusing on clinical research services for both domestic and international pharmaceutical and health-related products, covering phases I to IV of clinical trials [2][12]. Group 2: Strategic Partnerships and Developments - In July 2018, Tiger Med signed a strategic cooperation agreement with Jiuzhou Pharmaceutical, a leading CDMO service provider, to collaborate in the clinical research and development of innovative drugs [2][12]. - The subsidiary, Jietong Tairui, focuses on providing clinical research outsourcing services for medical devices, including registration and clinical trial services [2][12]. Group 3: Clinical Trials and Research - In 2023, the company initiated its first Phase I clinical trial for a herpes zoster protein vaccine in the U.S. and a Phase III trial for a quadrivalent meningococcal vaccine in Indonesia, enrolling over 1,400 participants [3][11]. - Tiger Med completed two large-scale Phase III efficacy studies for vaccines in collaboration with the Chinese Center for Disease Control and Prevention, with a total enrollment exceeding 38,000 participants [3][11]. Group 4: Technological Innovations - The subsidiary, Taiya Technology, developed an AI product platform for medical applications based on the open-source model Qwen2.5, providing solutions for new drug development, clinical trials, and registration [4][13]. - The AI platform has achieved excellent scores across five MedBench evaluation dimensions, including medical language understanding and generation, and is designed to enhance medical translation and knowledge inquiry [4][13]. Group 5: Financial Performance - For the year 2025, Tiger Med reported a revenue of 6.833 billion yuan, representing a year-on-year growth of 3.48%, and a net profit attributable to shareholders of 888 million yuan, up 119.15% [8][19]. - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan in the last three years [9][19].

Core Viewpoint - Junshi Biosciences is actively developing a monkeypox recombinant protein vaccine in collaboration with several prestigious institutions, indicating a strategic focus on innovative vaccine development and expanding its product pipeline [2][3]. Group 1: Company Developments - On October 27, 2023, Junshi Biosciences announced a partnership with Peking University, the Institute of Microbiology of the Chinese Academy of Sciences, Shanxi Higher Innovation Research Institute, and Beihang University to jointly develop a monkeypox recombinant protein vaccine [2]. - The company’s subsidiary, Junshi Biotech, holds vaccine-related product pipelines, including monkeypox and Zika vaccines, which are currently in preclinical development [2]. - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization [3]. Group 2: Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, representing a year-on-year growth of 42.06%, while the net profit attributable to shareholders was -596 million yuan, a year-on-year increase of 35.72% [9]. - The company’s main business revenue composition includes 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services and others [9]. Group 3: Product Pipeline and Innovations - Junshi Biosciences has developed a significant product portfolio, including the core product Toripalimab, which is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review [3]. - The company is also advancing Tifcemalimab, the first anti-BTLA monoclonal antibody to enter clinical development, with ongoing Phase III registration studies and multiple Phase I/II studies in various tumor types [3]. Group 4: Technological Advancements - The company has deployed an AI translation platform that has replaced over 80% of external translation services for scientific literature, clinical trials, and quality management [4]. - Junshi Biosciences has introduced a digital employee, "i Xiao Jun," powered by AI, to provide medical information, IT support, and internal knowledge queries for frontline sales [4].

Market Overview - On February 25, the Shanghai Composite Index rose by 0.72% to 4147.23 points, the Shenzhen Component Index increased by 1.29% to 14475.86 points, and the ChiNext Index climbed by 1.41% to 3354.82 points. The total trading volume in the Shanghai and Shenzhen markets reached 2.46 trillion yuan, an increase of approximately 260.48 billion yuan compared to the previous trading day. A total of 3540 stocks rose, 1529 fell, and 121 remained unchanged, with thematic sectors showing strong performance [1]. Popular Stocks - The top ten popular stocks in A-shares include Baogang Group, Aerospace Development, Changchun High-tech, Yuntianhua, Hancable, Northern Rare Earth, Hebang Biotechnology, Jinzhengdai, Chuanjinnuo, and Lioo [1][2]. Baogang Group - Baogang Group's market attention is driven by its advantages in rare earth resources and the effectiveness of its strategic transformation. The price of rare earth concentrate has been raised for the sixth consecutive time, indicating an improvement in its bargaining power within the rare earth industry chain. The production of rare earth steel reached a historical high of 1.5 million tons, supported by its exclusive supply rights from the world's largest rare earth mine [3]. Aerospace Development - Aerospace Development's rise in popularity is attributed to dual advancements in governance optimization and strategic layout. The company has recently completed a standardized board of directors' restructuring and revised several management systems. Its subsidiary, Aerospace Tianmu, is advancing the "Tianmu No. 1" satellite project through capital increase and expansion, enhancing its strategic positioning in military informationization and commercial aerospace [3]. Changchun High-tech - Changchun High-tech is gaining attention due to significant breakthroughs in the innovative drug sector. The company has received clinical approval for the world's first ointment for treating pediatric micropenis and has strong sales for its IL-1β monoclonal antibody. Additionally, it secured a $1.365 billion overseas business development contract, marking a substantial business increment [4]. Yuntianhua - Yuntianhua's market interest stems from its resource advantages and external demand. The company possesses nearly 800 million tons of phosphate reserves with a self-sufficiency rate of 100%. The production of its 100,000-ton iron phosphate project has commenced, and the upcoming spring farming season is expected to boost phosphate fertilizer demand [4]. Hancable - Hancable's popularity is driven by technological advantages underpinned by policy support. The State Grid's investment plan of 4 trillion yuan is expected to stimulate demand for high-end cables, particularly in ultra-high voltage and flexible direct current sectors. The company has core technologies in ±535kV submarine cables and has optimized its governance structure to enhance competitiveness [5]. Northern Rare Earth - Northern Rare Earth's market focus is influenced by policy, supply-demand dynamics, and performance. As a leader in the rare earth industry, the company benefits from national protection policies and the tightening of supply controls, which have improved the supply-demand balance and driven up rare earth prices. The company's net profit is expected to increase by 116.67% to 1.346 billion yuan [5]. Hebang Biotechnology - Hebang Biotechnology's rise is linked to resource layout and positive business developments. The company has obtained exploration rights for over 1,000 square kilometers of gold mines in Australia and is advancing multi-metal mining projects in Xinjiang. Its methionine business is experiencing growth, and external factors such as rising commodity prices are enhancing profitability [6]. Jinzhengdai, Chuanjinnuo, and Lioo - Jinzhengdai is benefiting from increased attention in the fertilizer industry, with rising domestic urea prices and improved governance structure. Chuanjinnuo is seeing a significant profit increase of 144%-180% due to international phosphate prices exceeding $700 per ton. Lioo has capitalized on AI marketing and liquid cooling server trends, achieving a net profit increase of 469.1% [6].

Core Viewpoint - The article discusses the performance and business operations of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., highlighting its growth in overseas revenue and the impact of currency depreciation on its financials [2][3]. Company Overview - Shenzhen Hepalink, established in 1998, is a leading multinational pharmaceutical company with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2]. - The company's main business segments include formulations (63.06%), CDMO (18.59%), heparin sodium and low molecular weight heparin raw materials (16.05%), and others (2.30%) [7]. Financial Performance - For the period from January to September 2025, Hepalink achieved a revenue of 4.194 billion yuan, representing a year-on-year growth of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. - The company reported that 93.04% of its revenue comes from overseas, benefiting from the depreciation of the Chinese yuan [3]. Market Activity - On February 25, Hepalink's stock rose by 0.74%, with a trading volume of 39.7381 million yuan and a turnover rate of 0.26%, leading to a total market capitalization of 17.945 billion yuan [1]. - The stock has seen a net outflow of 1.7001 million yuan from major investors, indicating a reduction in holdings over the past three days [4][5]. Technical Analysis - The average trading cost of Hepalink's shares is 11.67 yuan, with the stock currently near a support level of 12.23 yuan, suggesting potential for a rebound if this level holds [6].

Core Viewpoint - Changchun High-tech's stock price has shown fluctuations, with a recent increase of 2.04% and a total market capitalization of 36.804 billion yuan, despite a year-to-date decline of 2.52% [1] Financial Performance - For the period from January to September 2025, Changchun High-tech reported operating revenue of 9.807 billion yuan, a year-on-year decrease of 5.60%, and a net profit attributable to shareholders of 1.165 billion yuan, down 58.23% year-on-year [2] Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 4.63% to 104,100, while the average number of circulating shares per person increased by 4.85% to 3,840 shares [2] Dividend Distribution - Since its A-share listing, Changchun High-tech has distributed a total of 4.791 billion yuan in dividends, with 3.259 billion yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 1.307 million shares to 9.7451 million shares, while other institutional investors like Huatai-PB CSI 300 ETF and others have reduced their holdings [3]

Core Viewpoint - Junshi Biosciences is actively developing a monkeypox recombinant protein vaccine in collaboration with several prestigious institutions, indicating a strong focus on innovative vaccine development and a commitment to expanding its product pipeline in the biopharmaceutical sector [2][3]. Company Developments - On October 27, 2023, Junshi Biosciences announced a partnership with Peking University, the Institute of Microbiology of the Chinese Academy of Sciences, Shanxi Higher Innovation Research Institute, and Beihang University to jointly develop a monkeypox recombinant protein vaccine [2]. - The company’s subsidiary, Junshi Biotech, is involved in the development of various vaccine-related products, including monkeypox and Zika vaccines, which are currently in the preclinical development stage [2]. Product Pipeline and Achievements - Junshi Biosciences has a comprehensive capability in the entire industry chain from drug discovery and development to large-scale production and commercialization, aiming to become a global innovative pharmaceutical company based in China [3]. - The company’s core product, Toripalimab, is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review. It has also received approvals in multiple countries including the U.S., EU, and Australia [3]. - The company is advancing its proprietary drug tifcemalimab, which is the first anti-BTLA monoclonal antibody to enter clinical development, with ongoing Phase III clinical trials and several Phase Ib/II studies in various tumor types [3]. Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, representing a year-on-year growth of 42.06%. However, the net profit attributable to shareholders was a loss of 596 million yuan, although this reflects a 35.72% improvement compared to the previous year [9]. Technological Advancements - The company has deployed an AI translation platform that has replaced over 80% of external translation services for scientific literature, clinical trials, and quality management, enhancing operational efficiency [4]. Market Position - As of February 10, 2023, Junshi Biosciences had a market capitalization of 36.673 billion yuan, with a trading volume of 3.32 billion yuan and a turnover rate of 1.21% [1].

Core Viewpoint - Junshi Biosciences is actively developing a monkeypox recombinant protein vaccine in collaboration with several prestigious institutions, indicating a strategic focus on innovative vaccine development and expanding its product pipeline [2][3]. Group 1: Company Developments - On October 27, 2023, Junshi Biosciences announced a partnership with Peking University, the Institute of Microbiology of the Chinese Academy of Sciences, Shanxi Higher Innovation Research Institute, and Beihang University to jointly develop a monkeypox recombinant protein vaccine [2]. - The company’s subsidiary, Junshi Biotech, holds vaccine-related product pipelines, including monkeypox and Zika vaccines, which are currently in preclinical development [2]. - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization [3]. Group 2: Product Pipeline and Achievements - Junshi's core product, Toripalimab, is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review [3]. - The company has also developed Tifcemalimab, the world's first anti-BTLA monoclonal antibody entering clinical development, currently undergoing two Phase III registration clinical trials [3]. - Multiple products are expected to initiate critical registration clinical trials by 2025, showcasing the company's commitment to innovation [3]. Group 3: Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a 35.72% year-on-year growth [9]. - The company’s main business revenue composition includes 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [9]. Group 4: Technological Advancements - Junshi has deployed an AI translation platform that has replaced over 80% of external translation services across various fields, enhancing operational efficiency [4]. - The company has introduced a digital employee, "i Xiao Jun," powered by AI, to support sales with medical information queries and provide IT system support [4].

Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and has both A and H share financing platforms [2]. - The main business segments include heparin raw materials, low molecular weight heparin products, and CDMO services, with revenue contributions of 63.06% from formulations, 18.59% from CDMO, and 16.05% from heparin products [7]. - As of September 30, 2025, the company reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The total market capitalization of Haiprui is 18.062 billion yuan, with a trading volume of 52.6162 million yuan on February 9 [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 27,000, with an average of 0 circulating shares per person [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan in the last three years [8]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the eighth largest circulating shareholder, holding 12.0093 million shares, an increase of 691,700 shares from the previous period [9].

Core Viewpoint - New Nuo Wei's stock price has shown volatility, with a year-to-date decline of 1.91% and a significant drop of 8.98% over the past five trading days, while experiencing an increase of 11.86% over the last 60 days [2] Group 1: Stock Performance - On February 6, New Nuo Wei's stock rose by 2.05%, reaching a price of 35.38 yuan per share, with a trading volume of 1.05 billion yuan and a market capitalization of 49.694 billion yuan [1] - The stock has appeared on the "Dragon and Tiger List" once this year, with a net buy of -126 million yuan on January 30, where total purchases amounted to 314 million yuan, accounting for 21.64% of total trading volume, and total sales reached 440 million yuan, making up 30.30% of total trading volume [2] Group 2: Financial Performance - For the period from January to September 2025, New Nuo Wei reported a revenue of 1.593 billion yuan, reflecting a year-on-year growth of 7.71%, while the net profit attributable to shareholders was -24.049 million yuan, a decrease of 117.26% year-on-year [2] Group 3: Shareholder Information - As of January 30, 2025, New Nuo Wei had 17,500 shareholders, an increase of 0.28% from the previous period, with an average of 80,349 circulating shares per shareholder, a decrease of 0.27% [2] - The company has distributed a total of 651 million yuan in dividends since its A-share listing, with 500 million yuan distributed over the past three years [3] - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the second-largest shareholder with 17.7822 million shares, a decrease of 3.2169 million shares from the previous period [3]

Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise established in 1998, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization, aiming to provide high-quality and effective medications and services globally [2][3]. Group 1: Company Overview - Haiprui's main business segments include heparin sodium raw materials, downstream low molecular weight heparin products, and CDMO services, with revenue contributions of 63.06% from formulations, 18.59% from CDMO, and 16.05% from heparin products [7]. - As of September 30, 2025, Haiprui reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. - The company has a total market capitalization of 17.901 billion yuan, with a trading volume of 51.35 million yuan and a turnover rate of 0.34% on February 4 [1]. Group 2: Financial Performance - The overseas revenue proportion for Haiprui is 93.04%, benefiting from the depreciation of the Renminbi [3]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Group 3: Market Position and Trends - Haiprui is positioned within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is included in various concept boards such as the S&P Dow Jones China and FTSE Russell [7]. - The stock has shown a recent average trading cost of 11.66 yuan, with a current price near a resistance level of 12.37 yuan, indicating potential for upward movement if the resistance is broken [6].